Does Enbrel Cause Weight Gain?
Enbrel (etanercept), a TNF inhibitor for rheumatoid arthritis, psoriasis, and other autoimmune conditions, lists weight gain as a reported side effect in clinical trials and post-marketing data. In pivotal trials like TEMPO and COMET for rheumatoid arthritis, 2-5% of patients on Enbrel (alone or with methotrexate) gained at least 5% body weight over 6-12 months, compared to 1-3% on placebo or methotrexate alone.[1][2] Real-world studies, including a 2018 analysis of over 10,000 patients in the British Society for Rheumatology Biologics Register, found Enbrel users had a 1.5-2 kg average weight increase after one year, higher than non-TNF biologic users.[3]
Why Might Enbrel Lead to Weight Gain?
TNF-alpha blockers like Enbrel reduce inflammation, which can normalize appetite and metabolism disrupted by conditions like rheumatoid arthritis. Patients often report improved energy, leading to higher calorie intake or activity tolerance. A 2020 review in Rheumatology linked this to reduced cachexia (disease-related weight loss) rather than direct fat accumulation.[4] Hormonal shifts, like lower leptin resistance from inflammation control, may also play a role.[5]
How Common Is It Compared to Other Biologics?
Weight gain occurs in 3-10% of Enbrel users across indications, similar to Humira (adalimumab) at 4-8% but less than IL-17 inhibitors like Cosentyx (secukinumab), where rates exceed 15% in psoriasis trials.[1][6] In head-to-head data from the 2017 AMPLE trial, Enbrel and Humira showed comparable 2-4% incidence.[2]
| Drug | Weight Gain Rate (≥5% body weight, 1 year) |
|------|--------------------------------------------|
| Enbrel | 3-5%[1] |
| Humira | 4-8%[6] |
| Cosentyx | 10-15%[7] |
| Stelara | 2-4%[8] |
What Do Patients Report?
User forums like Drugs.com and PatientsLikeMe show mixed experiences: about 7% of 2,500+ Enbrel reviews mention weight gain (average 10-20 lbs over 6-18 months), often tied to better symptom control rather than complaint.[9] Some describe rapid gain in the first 3 months, stabilizing later.
Risk Factors and Management
Higher risk in women, older patients, or those with baseline low BMI/underweight from disease. Comorbidities like hypothyroidism amplify it. Doctors recommend monitoring BMI quarterly; lifestyle changes (diet, exercise) reverse most cases without stopping therapy.[4][10] No black-box warnings for weight gain, but FDA labels note it under "metabolic" effects.[1]
When Does It Happen and How Long Does It Last?
Onset typically within 1-6 months; peaks at 12 months, then plateaus. A 5-year open-label extension found sustained but minimal further gain (total ~3 kg).[2]
Sources
[1]: FDA Enbrel Label
[2]: Keystone et al., Arthritis Rheum 2008 (TEMPO/COMET)
[3]: Hyrich et al., Rheumatology 2018 (BSRBR)
[4]: Bhole et al., Rheumatology 2020 review
[5]: Di Munno et al., Clin Exp Rheumatol 2009
[6]: FDA Humira Label
[7]: FDA Cosentyx Label
[8]: FDA Stelara Label
[9]: Drugs.com Enbrel Reviews
[10]: ACR Guidelines 2021 (Biologics Management)